Metagenomi (MGX) Stock Price, News & Analysis

Company Overview

Metagenomi, Inc. is a biotechnology company focused on developing genetic medicines using gene-editing technologies. The company applies metagenomics, the study of genetic material recovered directly from environmental samples, to identify naturally occurring CRISPR and other genome-editing systems that may offer advantages over established tools.

Metagenomi is developing a pipeline of investigational therapies designed to address genetic diseases through in vivo and ex vivo gene editing. Its research activities include discovering and engineering novel editing systems, delivery methods and therapeutic approaches for potential use in human medicine. The company’s programs remain in development, and it does not have commercially marketed products.

Founded in 2018, Metagenomi is headquartered in Emeryville, California, and has pursued collaborations with pharmaceutical and biotechnology companies to advance its gene-editing platform. Brian C. Thomas, a co-founder of the company, serves as chief executive officer. Metagenomi began trading on the Nasdaq under the symbol MGX following its initial public offering in 2024.

Key Stats

• Today's Range: $0.99 to $1.04
• 50-Day Range: $0.98 to $1.24
• 52-Week Range: $0.96 to $3.95
• Volume: 146,836 shs
• Average Volume: 142,733 shs
• Market Capitalization: $37.78 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.00
• Consensus Rating: Moderate Buy

Metagenomi Stock Analysis - MarketRank™

Metagenomi scored higher than 77% of companies evaluated by MarketBeat, and ranked 292nd out of 883 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Metagenomi has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Metagenomi has a consensus price target of $6.00, representing about 500.0% upside from its current price of $1.00.

Amount of Analyst Coverage

Metagenomi has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Metagenomi are expected to grow in the coming year, from ($2.50) to ($1.76) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Metagenomi is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Metagenomi is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Metagenomi has a P/B Ratio of 0.24. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.85% of the float of Metagenomi has been sold short.

Short Interest Ratio / Days to Cover

Metagenomi has a short interest ratio ("days to cover") of 10.54, which indicates bearish sentiment.

Change versus previous month

Short interest in Metagenomi has recently decreased by 11.09%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Metagenomi does not currently pay a dividend.

Dividend Growth

Metagenomi does not have a long track record of dividend growth.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: N/A

News Sentiment

Metagenomi has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Metagenomi this week, compared to 1 article on an average week.

Search Interest

Only 2 people have searched for MGX on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $23,400.00 in company stock, which represents 0.0619% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Metagenomi insiders have bought more of their company's stock than they have sold. Specifically, they have bought $23,400.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

12.50% of the stock of Metagenomi is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Metagenomi has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 10/10/2026
• Next Earnings (Estimated): 11/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:MGX
• Previous Symbol: NASDAQ:MGX
• CIK: 1785279
• Web: www.metagenomi.co
• Phone: 510-871-4880
• Fax: N/A
• Employees: 113
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Metagenomi: $6.00
• High Price Target: $7.00
• Low Price Target: $5.00
• Potential Upside/Downside: +500.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.49)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$87.87 million
• Net Margins: -384.61%
• Pretax Margin: -690.60%
• Return on Equity: -63.65%
• Return on Assets: -44.52%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.50
• Quick Ratio: 4.50

Sales & Book Value

• Annual Sales: $25.21 million
• Price / Sales: 1.50
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.22 per share
• Price / Book: 0.24

Miscellaneous

• Outstanding Shares: 37,780,000
• Free Float: 33,055,000
• Market Cap: $37.78 million
• Optionable: N/A
• Beta: 0.69